VEGFA and ovarian carcinoma: The expression of VEGF-A and its receptor (VEGFR2/KDR) in epithelial ovarian cancer facilitated anoikis resistance, and the targeting of VEGF-A using a neutralizing antibody or KDR using a specific inhibitor sensitized the cells to anoikis (51).